Thursday, February 02, 2023 6:39:30 PM
So in my mind, I don't think it would be wrong at all for Revive to ask for half of that 22 Billion that was spoken of.
If BP is just going to "inherit" the formula, and just have to reproduce it to turn it around to make a profit. Let's say that then turns into a 22 Billion cow for them, it is only reasonable for them to pony up half of what they will make.
I know business doesn't work that way, because BBP will come back and feign legal fees, overhead, yadda-yippee. But they aren't doing the hard legwork. They're basically going to get a free pass to Go. Calling all Monopoly fans.
If BP is just going to "inherit" the formula, and just have to reproduce it to turn it around to make a profit. Let's say that then turns into a 22 Billion cow for them, it is only reasonable for them to pony up half of what they will make.
I know business doesn't work that way, because BBP will come back and feign legal fees, overhead, yadda-yippee. But they aren't doing the hard legwork. They're basically going to get a free pass to Go. Calling all Monopoly fans.
Bullish
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
